The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Targeting the Bcl-2-regulated apoptosis pathway by BH3 mimetics: a breakthrough in anticancer therapy?
Open accessAbstract
Induction of apoptosis in tumor cells by direct activation of the Bcl-2-regulated apoptosis pathway by small molecule drugs carries high hopes to overcome the shortcomings of current anticancer therapies. This novel therapy concept builds on emerging insights into how Bcl-2-like molecules maintain mitochondrial integrity and how pro-apoptotic BH3-only proteins lead to its disruption. Means to unleash the pro-apoptotic potential of BH3-only proteins in tumor cells, or to bypass the need for BH3-only proteins by directly blocking possible interactions of Bcl-2-like pro-survival molecules with Bax and/or Bak, constitute interesting options for the design of novel anticancer therapies. For the optimization and clinical implementation of these novel anticancer strategies, a detailed understanding of the role of individual BH3-only proteins in cell death signaling in healthy cells and during tumor suppression is required. In this review, we will touch on the latest findings on BH3-only protein function and attempts to define the molecular properties of the so-called ‘BH3 mimetics,’ a novel class of anticancer agents, able to prompt apoptosis in tumor cells, regardless of their p53 or Bcl-2 status.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Noxa, a BH3-Only Member of the Bcl-2 Family and Candidate Mediator of p53-Induced Apoptosis
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T., Tokino, T., Taniguchi, T., & Tanaka, †. N. (2000) · Science · doi:10.1126/science.288.5468.1053 · Cited by 2,112
Chen, L., Willis, S. N., Wei, A., Smith, B. J., Fletcher, J. I., Hinds, M. G., Colman, P. M., Day, C. L., Adams, J. M., & Huang, D. C. S. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.12.030 · Cited by 1,816
Letai, A., Bassik, M. C., Walensky, L. D., Sorcinelli, M. D., Weiler, S., & Korsmeyer, S. J. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00127-7 · Cited by 1,677
Lindsten, T., Ross, A. J., King, A., Zong, W.-X., Rathmell, J. C., Shiels, H. A., Ulrich, E., Waymire, K. G., Mahar, P., Frauwirth, K., et al. (2000) · Molecular Cell · doi:10.1016/s1097-2765(00)00136-2 · Cited by 1,489
Activation of Apoptosis in Vivo by a Hydrocarbon-Stapled BH3 Helix
Walensky, L. D., Kung, A. L., Escher, I., Malia, T. J., Barbuto, S., Wright, R. D., Wagner, G., Verdine, G. L., & Korsmeyer, S. J. (2004) · Science · doi:10.1126/science.1099191 · Cited by 1,349
IAP Antagonists Induce Autoubiquitination of c-IAPs, NF-κB Activation, and TNFα-Dependent Apoptosis
Varfolomeev, E., Blankenship, J. W., Wayson, S. M., Fedorova, A. V., Kayagaki, N., Garg, P., Zobel, K., Dynek, J. N., Elliott, L. O., Wallweber, H. J. A., et al. (2007) · Cell · doi:10.1016/j.cell.2007.10.030 · Cited by 1,218
Kuwana, T., Bouchier-Hayes, L., Chipuk, J. E., Bonzon, C., Sullivan, B. A., Green, D. R., & Newmeyer, D. D. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.003 · Cited by 1,185
Programmed Anuclear Cell Death Delimits Platelet Life Span
Mason, K. D., Carpinelli, M. R., Fletcher, J. I., Collinge, J. E., Hilton, A. A., Ellis, S., Kelly, P. N., Ekert, P. G., Metcalf, D., Roberts, A. W., et al. (2007) · Cell · doi:10.1016/j.cell.2007.01.037 · Cited by 1,031
Bcl-2 family proteins are essential for platelet survival
Zhang, H., Nimmer, P. M., Tahir, S. K., Chen, J., Fryer, R. M., Hahn, K. R., Iciek, L. A., Morgan, S. J., Nasarre, M. C., Nelson, R., et al. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402081 · Cited by 427
Verhaegen, M., Bauer, J. A., Martín de la Vega, C., Wang, G., Wolter, K. G., Brenner, J. C., Nikolovska-Coleska, Z., Bengtson, A., Nair, R., Elder, J. T., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1748 · Cited by 140
Cited by
Structure-guided design of a selective BCL-XL inhibitor
Lessene, G., Czabotar, P. E., Sleebs, B. E., Zobel, K., Lowes, K. N., Adams, J. M., Baell, J. B., Colman, P. M., Deshayes, K., Fairbrother, W. J., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1246 · Cited by 381
Bcl2 family proteins in carcinogenesis and the treatment of cancer
Frenzel, A., Grespi, F., Chmelewskij, W., & Villunger, A. (2009) · Apoptosis · doi:10.1007/s10495-008-0300-z · Cited by 331
Self-citationMcl-1 is a potential therapeutic target in multiple types of cancer
Akgul, C. (2009) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-008-8637-6 · Cited by 329
Estrogenic control of mitochondrial function and biogenesis
Klinge, C. M. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21936 · Cited by 318
Labi, V, & Erlacher, M. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.20 · Cited by 295
Self-citationThe Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma
Touzeau, C., Dousset, C., Le Gouill, S., Sampath, D., Leverson, J. D., Souers, A. J., Maïga, S., Béné, M. C., Moreau, P., Pellat-Deceunynck, C., et al. (2014) · Leukemia · doi:10.1038/leu.2013.216 · Cited by 289
Noxa: at the tip of the balance between life and death
Ploner, C., Kofler, R., & Villunger, A. (2008) · Oncogene · doi:10.1038/onc.2009.46 · Cited by 283
Self-citationHistone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights
Bose, P., Dai, Y., & Grant, S. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.04.004 · Cited by 280
The mitochondrial death pathway: a promising therapeutic target in diseases
Gupta, S., Kass, G. E. N., Szegezdi, E., & Joseph, B. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00697.x · Cited by 278
Moreau, P., Chanan-Khan, A., Roberts, A. W., Agarwal, A. B., Facon, T., Kumar, S., Touzeau, C., Punnoose, E. A., Cordero, J., Munasinghe, W., et al. (2017) · Blood · doi:10.1182/blood-2017-06-788323 · Cited by 271
The Mitochondrial Chaperone TRAP1 Promotes Neoplastic Growth by Inhibiting Succinate Dehydrogenase
Sciacovelli, M., Guzzo, G., Morello, V., Frezza, C., Zheng, L., Nannini, N., Calabrese, F., Laudiero, G., Esposito, F., Landriscina, M., et al. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.019 · Cited by 264
Ganesan, P., Noda, K., Manabe, Y., Ohkubo, T., Tanaka, Y., Maoka, T., Sugawara, T., & Hirata, T. (2011) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2011.02.008 · Cited by 187
Molecular and cellular mechanisms of CLL: novel therapeutic approaches.
Pleyer, L., Egle, A., Hartmann, T. N., & Greil, R. (2009) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2009.72 · Cited by 125
Metadata
- Authors
- Labi, V, Grespi, F., Baumgartner, F., & Villunger, A.
- Venue
- Cell Death & Differentiation
- Published
- 2008-03-28
- Volume
- 15
- Issue
- 6
- Pages
- 977-987
- ISSN
- 1350-9047 (ISSN-L)
- 1476-5403
- OpenAlex
- W1992947847
- Cited by
- 165
- References
- 10
- FWCI
- 7.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.